At AAAAI 2026, Robert Wood, MD, of Johns Hopkins University discusses remibrutinib, omalizumab, and OIT for treating food ...

Final stage of the OUtMATCH trial tracks outcomes for oral immunotherapy versus omalizumab ...

At AAAAI 2026, Robert Wood, MD, of Johns Hopkins University School of Medicine, discusses the use of omalizumab vs OIT for treating food allergy.

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

Please provide your email address to receive an email when new articles are posted on . Black patients with peanut allergies received oral immunotherapy less frequently than white patients. Patients ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of ...

A recent study attempted to determine the prevalence of eosinophilic esophagitis (EoE) in a group of patients allergic to milk or egg and undergoing oral immunotherapy (OIT) to those foods, as well as ...

Nearly 70% of children with low-risk peanut allergy tolerated a peanut oral food challenge, negating the need for allergy treatment, data from one center showed. Researchers sought to determine how ...